Wrapping up #DAVAWhistlerHeme with teaser from Dr. Paolo Strati MD Anderson Cancer Center, phase 1 trial of evorpacept and R2 for treatment of pts with r/r B-NHL

Evorpacept increases antibody-dependent phagocytosis in macrophages

Tune in to AACR on April 9th to see the results!

Will novel agents in CLL decrease risk of RT? Dr. Jean-Nicolas Champagne shares data from 219 RT patients, 144 pre- and 75 post-2016.

Post 2016:
⬆️Time from txt to RT
⬇️PS at time of RT
⬇️OS after RT

RT remains challenging. More tolerable therapies are needed in the modern era.

Dr. John Baird returns to the stage to discuss BAFF-R as a target to overcome antigen escape mechanisms of resistance

DL2 currently enrolling in MCL, LBCL, FL, MZL: classic.clinicaltrials.gov/ct2/show/NCT05…
Ph 1 for B-ALL also enrolling: clinicaltrials.gov/study/NCT04690…

L. Elizabeth Budde, M.D., Ph.D.
City of Hope

CD30 CAR-T has been disappointing in HL.

Dr. Jakub Svoboda shares 'engine fine tuning' w/ CRISPR knock out BTLA-HVEM, a CPI that is enriched in HL and suppresses immune activation

Murine models show enhanced CD30 CAR-T function with BTLA KO, clinical trials in planning stage

Dr. Jakub Svoboda Penn Medicine discusses armored huCART19-IL18 with encouraging early results in CD19+ lymphoma

No new safety signals w/ IL-18
CRS/ICANS rates comparable, reversible
82% ORR at 3 mo

Enrollment completed for NHL and continues for CLL, ALL
clinicaltrials.gov/study/NCT04684…

Dr. John Baird City of Hope shares promising phase 1 experience of CRG-022 in LBCL after prior autologous CAR-T

Pivotal phase 2 trial now enrolling: classic.clinicaltrials.gov/ct2/show/NCT05…

A fantastic final MM lecture of #DAVAWhistlerHeme !

Scott Goldsmith shares preclinical efficacy of Actinium-225-DOTA daratumumab radioimmunotherapy and ongoing clinical trial for triple-class refractory MM

clinicaltrials.gov/study/NCT05363…

Which is your favorite candidate name? 😅

Dr. Craig Portell UVA discusses the biology of CDK9 in CLL and rationale for targeting this protein

CDK9 affects MCL-1 which is overexpressed in some CLL patients with acquired venetoclax resistance

Unlikely to be used as monotherapy, but phase 1 combination trials are ongoing

Dr. Stephen Spurgeon provides 14-mo update to waveLINE-001 trial. Notably, there is a signal in MCL, with 100% of MCL patients BTKi-exposed and 82% with PD on BTKi.

ZV could be a potential salvage therapy for these MCL patients

ROR-1 is an appealing target for CAR, BsAbs, etc

Fascinating ctDNA work from Dr. Brian Sworder UCI Health

➖Dynamic ctDNA levels prognostic for outcome in CAR19 pts
➖Emerging resistance mutations can be identified non-invasively with ctDNA
➖Multiple genes involved in resistance including PAX5, IRF8, TMEM30A, CD19, PD-L1

Dr. Daniel Landsburg shares data from Penn demonstrating superior freedom from treatment failure with ASCT versus CAR-T at multiple time points despite well balanced risk factors between groups.

36-mo FFTF ASCT: 59%
36-mo FFTF CAR-T: 24%

Dr. Matthew McKinney Duke Cancer shares a detailed exploration of targetable mutations in hepatosplenic γδ T-cell lymphoma, emphasizing the heterogeneity in target expression.

Individual precision medicine will be needed to move beyond allo/auto SCT in this patient population.

'Let food be thy medicine...'

Microbiome, specifically ⬆️ butyrate producers, impacts on myeloma progression and sustained MRD negativity after treatment

Seafood, plant protein have greatest impact on butyrate. Dietary interventions have been promising!

Urvi Shah
AlexanderLesokhin MD

In healthy individuals, exercise enhances immune surveillance including ⬆️ NK cell recognition and killing of tumor cells.

Andrea Sitlinger conducted a pilot study for HIIT training in treatment naive CLL patients.

Patients experienced improved QOL and improved NK function. 💪

Dr. Alessandra Ferrajoli MD Anderson Cancer Center opens our final day of #DAVAWhistlerHeme with a focus on survivorship.

CLL pts are at risk of hypogammaglobulinemia, autoimmune dx, suboptimal vaccine response, and excess second malignancies.

Screening and early intervention is key!

The final day of #DAVAWhistlerHeme starts in just over half an hour!

Be sure to register and join us live for the final sessions and view the last three day's worth of amazing content on demand.

dava.link/whistler24

Dr. Vivian Oehler rounds out panel with a call for biomarkers to identify CML patients who can benefit from escalation of initial therapy, highlighting work from Dr. Vaidehi Krishnan et al using single-cell atlas to identify primary imatinib resistance

ashpublications.org/blood/article-…

Very glad to have Dr. Tony Hunter discussing the latest advances for SM. In the words of Kristen Pettit 'who would have thought SM would be so exciting!'

Promising early clinical data for Bezuclastinib, with trials now enrolling

classic.clinicaltrials.gov/ct2/show/NCT04…
classic.clinicaltrials.gov/ct2/history/NC…

New PV therapies are needed to address inflammation, BM microenvironment, and specific genetic mutations.

A phase II trial of Bomedemstat in PV patients has completed enrollment! Looking forward to results at an upcoming conference.

clinicaltrials.gov/study/NCT05558…

Lindsay Rein

Dr. Rachel Salit discusses the OS benefit of using JAK-inhibitors prior to HCT to minimize risks specific to MF pts such as BM fibrosis and splenomegaly

Ruxolitinib is now approved for treatment of GVHD, demonstrating utility of continuing JAK-inhibitors after transplant